Skip to main content

Table 1 Baseline characteristics of study population according to SHR cut-off

From: Stress hyperglycemia ratio as a prognostic indicator for long-term adverse outcomes in heart failure with preserved ejection fraction

 

All patients

(n = 400)

Patients with

SHR > 0.99 (n = 124)

Patients with

SHR ≤ 0.99 (n = 276)

P value

Baseline variables

    

Age (years)

71.0 ± 7.8

71.1 ± 8.3

70.9 ± 7.6

0.896

Female, n (%)

226 (56.5)

67 (54.0)

159 (57.6)

0.505

BMI (kg/m2)

25.2 ± 3.8

25.2 ± 4.3

25.2 ± 3.6

0.989

NYHA class III-IV, n (%)

201 (50.3)

73 (58.9)

128 (46.4)

0.021

Systolic BP (mmHg)

140.9 ± 23.2

137.8 ± 24.2

142.3 ± 22.6

0.074

Diastolic BP (mmHg)

77.9 ± 13.5

77.3 ± 14.5

78.2 ± 13.0

0.538

Heart rate

80.8 ± 17.2

83.8 ± 19.6

79.5 ± 15.9

0.022

Comorbidities, n (%)

    

CHD

162 (40.5)

52 (41.9)

110 (39.9)

0.695

Atrial fibrillation

103 (25.8)

40 (32.3)

63 (22.8)

0.046

Alcohol

43 (10.8)

16 (12.9)

27 (9.8)

0.351

Smoking

86 (21.5)

34 (27.4)

52 (18.8)

0.053

Hypertension

298 (74.5)

86 (69.4)

212 (76.8)

0.114

Diabetes

166 (41.5)

58 (46.8)

108 (39.1)

0.151

Chronic Kidney Disease

52 (13.0)

24 (19.4)

28 (10.1)

0.011

Hyperlipidemia

124 (31.0)

46 (37.1)

78 (28.3)

0.077

Laboratory data

    

HbA1c (g/L) (%)

6.6 ± 1.3

6.7 ± 1.5

6.5 ± 1.1

0.059

ABG (µmol/L)

6.9 ± 2.7

9.4 ± 3.0

5.8 ± 1.5

< 0.001

Haemoglobin, g/dL

126.9 ± 19.1

123.0 ± 22.3

128.7 ± 17.3

0.005

TSH (mg/l)

3.8 ± 9.0

4.1 ± 10.4

3.8 ± 8.4

0.795

ALT

26.5 ± 24.9

28.4 ± 20.6

25.6 ± 26.6

0.297

Troponin T

0.06 ± 0.1

0.08 ± 0.1

0.05 ± 0.1

0.032

NT-proBNP (pg/mL)

1127.0 (573.8-2216.3)

1476.5 (774.5-2985.5)

946.0 (485-2010.5)

< 0.001

LDL

2.1 ± 0.8

2.1 ± 0.8

2.1 ± 0.8

0.463

Total cholesterol (mmol/L)

3.9 ± 1.1

4.0 ± 1.2

3.9 ± 1.1

0.386

Creatinine (mg/dl)

90.3 ± 39.6

98.7 ± 48.3

86.7 ± 34.7

0.006

eGFR

70.5 ± 23.5

68.9 ± 22.2

71.2 ± 24.1

0.357

Blood urea

7.6 ± 6.4

8.6 ± 5.4

7.1 ± 6.7

0.036

Potassium (mmol/L)

4.0 ± 0.6

3.9 ± 0.7

4.0 ± 0.6

0.286

C-reactive protein

3.3 (3.0-6.3)

4.7 (3.1–8.7)

3.2 (3.0-5.8)

0.001

Medication data

    

Beta-blockers

242 (60.5)

76 (61.3)

166 (60.1)

0.828

Diuretics

192 (48.0)

70 (56.5)

122 (44.2)

0.023

MCRA

129 (32.3)

45 (36.3)

84 (30.4)

0.247

Calcium channel blockers

124 (31.0)

32 (25.8)

92 (33.3)

0.132

ACEI + ARB

197 (49.3)

58 (46.8)

139 (50.4)

0.507

Statins

335 (83.8)

99 (79.8)

236 (85.5)

0.155

Echocardiography

    

LAVI, mL/m2

42.6 ± 6.2

43.3 ± 6.4

42.3 ± 6.0

0.149

LVEDD (mm)

47.4 ± 5.6

48.2 ± 5.6

47.0 ± 5.6

0.038

LVESD (mm)

31.8 ± 6.8

33.4 ± 7.9

31.1 ± 6.1

0.002

LVEF (%)

60.5 ± 5.0

59.6 ± 4.6

60.9 ± 5.1

0.015

e’, cm/s

7.0 (6.0–8.0)

6.0 (5.0–8.0)

7.0 (6.0–8.0)

0.020

Septal E/e’

15.0 ± 3.0

15.6 ± 3.4

14.7 ± 2.8

0.006

PASP

38.7 ± 11.4

39.5 ± 13.3

38.3 ± 10.4

0.333

  1. SHR: stress hyperglycemia ratio; BMI: body mass index; NYHA class: New York heart association; BP: blood pressure; CHD: coronary heart disease; HbA1c: glycated hemoglobin; ABG: admission blood glucose; TSH: thyroid stimulating hormone; ALT: alanine aminotransferase; NT-proBNP: N-terminal pro–B-type natriuretic peptide; LDL: low-density lipoprotein; eGFR: estimated glomerular filtration rate; MCRA: mineralocorticoid receptor antagonist; ACEI + ARB: angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; LAVI: left atrial volume index; LVEDD: left ventricular end-diastolic diameter; LVESD: left ventricular end-systolic diameter; LVEF: left ventricular ejection fraction; e’: peak LV velocity; E/e’: mean septal velocity; PASP: pulmonary artery systolic pressure